Comparing the current results to its competitors, 89bio Inc reported Revenue decrease in the 2 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.36 %, recorded in the same quarter.
89bio Inc 's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by rapid innovation and technological advancements. Key competitive factors for pegozafermin and future product candidates include efficacy, safety and tolerability, reliability, dosing convenience, price, generic competition, and reimbursement. Competitors consist of multinational pharmaceutical companies, specialized biotechnology firms, universities, and other research institutions. Numerous biotechnology and pharmaceutical companies are developing or marketing pharmaceuticals targeting the same diseases as pegozafermin. Additionally, smaller or early-stage companies may be significant competitors, particularly through collaborations with large, established companies.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
Sources:
89bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 89bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
